Highlights

Building blocks for new medicines

Building blocks for new medicines

The MWC uses New Zealand’s outstanding medicinal chemistry expertise to discover new medicines. A particular kind of chemistr...

read the full story

One cancer gene – but several different proteins

One cancer gene – but several different proteins

Cancer arises due to changes in DNA in a single cell.  Many changes are needed over time to a cell’s DNA to make it cancerous...

read the full story

Turning the tables on cancer

Turning the tables on cancer

Tumours often contain areas with less oxygen than is found in normal tissues. These areas are less vulnerable to many forms o...

read the full story

Mid-term review sets future direction

Mid-term review sets future direction

A comprehensive independent assessment found the Centre to be performing at a high level, producing distinct and positive ben...

read the full story

Smarter drug design

Smarter drug design

An advanced experimental technique linked to high powered computation is becoming an increasingly important tool for MWC rese...

read the full story

MWC welcomes landmark results for lung cancer drug

MWC welcomes landmark results for lung cancer drug

A novel lung cancer drug with strong development links to the MWC has shown impressive results in a large-scale international...

read the full story

Newly funded research highlights MWC collaborations

Newly funded research highlights MWC collaborations

A five-year research programme aims to develop nontoxic vaccine technologies to complement existing cancer immunotherapies.

read the full story

The tumour-promoting activities of a famous protein

The tumour-promoting activities of a famous protein

Developing new cancer therapies and a more reliable test for prostate cancer are just some of the potential outcomes of Mauri...

read the full story

MWC leads cancer immune therapy conversation

MWC leads cancer immune therapy conversation

The Maurice Wilkins Centre continues to be part of an international drive to develop and improve immune therapy for cancer. I...

read the full story

Cancer drug advances to phase II clinical trials

Cancer drug advances to phase II clinical trials

A New Zealand cancer drug developed by two Maurice Wilkins Centre investigators has reached the second phase of clinical tria...

read the full story

New therapies - from a new generation (2013)

New therapies - from a new generation (2013)

Nurturing the next generation of scientists is an important part of the Maurice Wilkins Centre’s work – and senior students c...

read the full story

New chemistry transforms cancer vaccine (2013)

New chemistry transforms cancer vaccine (2013)

A new kind of chemistry that dramatically simplifies the manufacture of cancer vaccines was created this year by Honours stud...

read the full story

Major new cancer vaccine programme (2010)

Major new cancer vaccine programme (2010)

Maurice Wilkins Centre investigators are involved in a major new research programme that aims to develop and trial anti-cance...

read the full story

The future of vaccines (2012)

The future of vaccines (2012)

Maurice Wilkins Centre investigator Professor Sarah Hook from the University of Otago is developing new vaccine formulations ...

read the full story

A licence to manufacture medicines (2012)

A licence to manufacture medicines (2012)

A licence to manufacture medicines has been granted to a University of Auckland facility that will produce the active ingredi...

read the full story

Exquisite networks (2011)

Exquisite networks (2011)

Innovative technology developed to study the heart has been adapted for a unique study of the immune system – and will now be...

read the full story

Mapping cellular networks (2010)

Mapping cellular networks (2010)

Maurice Wilkins Centre PhD student Daniel Hurley and colleagues are mapping signalling networks in cancer and have identified...

read the full story

Drug selection a milestone for spin-out (2010)

Drug selection a milestone for spin-out (2010)

In 2010 Maurice Wilkins Centre investigators Professors Bill Denny and Peter Shepherd selected a new anticancer drug candidat...

read the full story